Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420

XXXX tested the adjuvant combination of Irinotecan and temozolomide after initial chemoradiation in a single arm phase II study of newly diagnosed glioblastoma. The doublet regimen given for 12 months is substantially more toxic and does not appear to extend overall survival compared to temozolomide alone given for 6 months, with a potential benefit for the combination regimen only in the best prognostic group, RPA Class III.

https://ift.tt/2BzHtok